Want to join the conversation?
$MRK said the US FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA, an anti-PD-1 therapy for treating patients with advanced non-small cell lung cancer whose tumors express PD-L1, with a target action date of Dec. 24. FDA also granted Breakthrough Therapy Designation for this indication.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?